Literature DB >> 22561482

Reporting bias in industry-supported medication trials presented at the American Psychiatric Association meeting.

Srijan Sen, Maya Prabhu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561482      PMCID: PMC4013544          DOI: 10.1097/JCP.0b013e318253d737

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  7 in total

1.  Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Authors:  Bodil Als-Nielsen; Wendong Chen; Christian Gluud; Lise L Kjaergard
Journal:  JAMA       Date:  2003-08-20       Impact factor: 56.272

2.  Psychiatrists' relationships with pharmaceutical companies: part of the problem or part of the solution?

Authors:  Thomas R Insel
Journal:  JAMA       Date:  2010-03-24       Impact factor: 56.272

3.  Generic fluoxetine and choice of antidepressant medication.

Authors:  Michael J Sernyak; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

4.  Utilization, price, and spending trends for antidepressants in the US Medicaid Program.

Authors:  Yan Chen; Christina M L Kelton; Yonghua Jing; Jeff J Guo; Xing Li; Nick C Patel
Journal:  Res Social Adm Pharm       Date:  2008-08-08

5.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

6.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

7.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.